Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases

Helge HO Müller,1,2 Sebastian Moeller1 1Lehrstuhl für Integrative Psychiatrie und Psychotherapie, Universität Witten/Herdecke gGmbH, Witten, 58448, Germany; 2Gemeinschaftskrankenhaus Herdecke, Abteilung für Psychiatrie und Psychotherapie, Herdecke, GermanyCorrespo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Müller HHO, Moeller S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	drug-induced schizophrenia negative symptoms side effects weight cardiac safety Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/17fd112a29384befb7777c2684f485e6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:17fd112a29384befb7777c2684f485e6
record_format	dspace
spelling	oai:doaj.org-article:17fd112a29384befb7777c2684f485e62021-12-02T14:18:30ZDecline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases1178-2021https://doaj.org/article/17fd112a29384befb7777c2684f485e62021-04-01T00:00:00Zhttps://www.dovepress.com/decline-in-psychotic-symptoms-in-addition-to-cardiac-and-metabolic-saf-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Helge HO Müller,1,2 Sebastian Moeller1 1Lehrstuhl für Integrative Psychiatrie und Psychotherapie, Universität Witten/Herdecke gGmbH, Witten, 58448, Germany; 2Gemeinschaftskrankenhaus Herdecke, Abteilung für Psychiatrie und Psychotherapie, Herdecke, GermanyCorrespondence: Helge HO MüllerLehrstuhl für Integrative Psychiatrie und Psychotherapie, Universität Witten/Herdecke gGmbH, Alfred-Herrhausen-Straße 50, Witten, 58448, GermanyTel +49 2330 62-3167Fax +49 2330 62-3338Email helge.mueller@uni-wh.deAbstract: Cariprazine is a highly effective antipsychotic medication of the latest generation. Due to its special receptor profile with D2/D3 partial agonism and high D3 affinity, the use of cariprazine is particularly justified in negative psychotic symptomatic and cardiac prestressed patients or in patients with weight management problems. In this case series, two cases and the outcomes during the switch to cariprazine treatment under these conditions are described.Keywords: drug-induced, schizophrenia, negative symptoms, side effects, weight, cardiac safetyMüller HHOMoeller SDove Medical Pressarticledrug-inducedschizophrenianegative symptomsside effectsweightcardiac safetyNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 1089-1093 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	drug-induced schizophrenia negative symptoms side effects weight cardiac safety Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	drug-induced schizophrenia negative symptoms side effects weight cardiac safety Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Müller HHO Moeller S Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
description	Helge HO Müller,1,2 Sebastian Moeller1 1Lehrstuhl für Integrative Psychiatrie und Psychotherapie, Universität Witten/Herdecke gGmbH, Witten, 58448, Germany; 2Gemeinschaftskrankenhaus Herdecke, Abteilung für Psychiatrie und Psychotherapie, Herdecke, GermanyCorrespondence: Helge HO MüllerLehrstuhl für Integrative Psychiatrie und Psychotherapie, Universität Witten/Herdecke gGmbH, Alfred-Herrhausen-Straße 50, Witten, 58448, GermanyTel +49 2330 62-3167Fax +49 2330 62-3338Email helge.mueller@uni-wh.deAbstract: Cariprazine is a highly effective antipsychotic medication of the latest generation. Due to its special receptor profile with D2/D3 partial agonism and high D3 affinity, the use of cariprazine is particularly justified in negative psychotic symptomatic and cardiac prestressed patients or in patients with weight management problems. In this case series, two cases and the outcomes during the switch to cariprazine treatment under these conditions are described.Keywords: drug-induced, schizophrenia, negative symptoms, side effects, weight, cardiac safety
format	article
author	Müller HHO Moeller S
author_facet	Müller HHO Moeller S
author_sort	Müller HHO
title	Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
title_short	Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
title_full	Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
title_fullStr	Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
title_full_unstemmed	Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
title_sort	decline in psychotic symptoms in addition to cardiac and metabolic safety with cariprazine after poor response to previous antipsychotic treatments – a series of two cases
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/17fd112a29384befb7777c2684f485e6
work_keys_str_mv	AT mullerhho declineinpsychoticsymptomsinadditiontocardiacandmetabolicsafetywithcariprazineafterpoorresponsetopreviousantipsychotictreatmentsndashaseriesoftwocases AT moellers declineinpsychoticsymptomsinadditiontocardiacandmetabolicsafetywithcariprazineafterpoorresponsetopreviousantipsychotictreatmentsndashaseriesoftwocases
_version_	1718391591869087744

Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments &ndash; A Series of Two Cases

Ejemplares similares

Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases